Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Ixazomib-induced Sweet's syndrome.

Suyama T, Ito S, Shinagawa A.

Int J Hematol. 2019 Dec 11. doi: 10.1007/s12185-019-02797-6. [Epub ahead of print] No abstract available.

PMID:
31828594
2.

FDG-PET/MRI with high-resolution DWI characterises the distinct phenotypes of endometrial cancer.

Tsuyoshi H, Tsujikawa T, Yamada S, Chino Y, Shinagawa A, Kurokawa T, Okazawa H, Yoshida Y.

Clin Radiol. 2019 Nov 27. pii: S0009-9260(19)30636-1. doi: 10.1016/j.crad.2019.10.018. [Epub ahead of print]

PMID:
31785782
3.

Human parvovirus B19-associated encephalopathy with hereditary spherocytosis.

Shinagawa A, Fumimoto R, Nakamura Y, Katsuta T, Yamamoto H.

Pediatr Int. 2019 Sep;61(9):922-923. doi: 10.1111/ped.13960. No abstract available.

PMID:
31569290
4.

Large Hiatal Hernia Repair with Urinary Bladder Matrix Graft Reinforcement and Concomitant Sleeve Gastrectomy.

Sasse KC, Gevorkian J, Lambin R, Afshar R, Gardner A, Mehta A, Lambin JH, Shinagawa A.

JSLS. 2019 Jan-Mar;23(1). pii: e2018.00106. doi: 10.4293/JSLS.2018.00106.

5.

Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.

Tanaka K, Toyota S, Akiyama M, Wakimoto N, Nakamura Y, Najima Y, Doki N, Kakihana K, Igarashi A, Kobayashi T, Ohashi K, Kudo D, Shinagawa A, Takano H, Fujio T, Okoshi Y, Hori M, Kumagai T, Saito T, Mukae J, Yamamoto K, Tsutsumi I, Komeno T, Yoshida C, Yamamoto M, Kojima H; on behalf of the Ochanomizu Hematology Study Group.

Acta Haematol. 2019;141(2):111-118. doi: 10.1159/000495338. Epub 2019 Feb 6.

PMID:
30726834
6.

Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.

Nishikii H, Kurita N, Shinagawa A, Sakamoto T, Kusakabe M, Yokoyama Y, Kato T, Sakata-Yanagimoto M, Obara N, Hasegawa Y, Nakamura N, Chiba S.

Case Rep Hematol. 2019 Jan 3;2019:9710790. doi: 10.1155/2019/9710790. eCollection 2019.

7.

The ideal strategy for cervical cancer screening in Japan: Result from the Fukui Cervical Cancer Screening Study.

Kurokawa T, Onuma T, Shinagawa A, Chino Y, Kobayashi M, Yoshida Y.

Cytopathology. 2018 Aug;29(4):361-367. doi: 10.1111/cyt.12576. Epub 2018 Jun 21.

PMID:
29768678
8.

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.

Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, Kosugi H, Yoon SS, Huang SY, Qin X, Qi M, Iida S.

Blood Cancer J. 2018 May 1;8(4):41. doi: 10.1038/s41408-018-0071-x.

9.

Evaluation of the benefit and use of the new terminology in endometrial cytology reporting system.

Shinagawa A, Kurokawa T, Yamamoto M, Onuma T, Tsuyoshi H, Chino Y, Iwasaki K, Mori M, Imamura Y, Yoshio Y.

Diagn Cytopathol. 2018 Apr;46(4):314-319. doi: 10.1002/dc.23901. Epub 2018 Feb 19.

PMID:
29460481
10.

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.

Iida S, Ichinohe T, Shinagawa A, Suzuki K, Takezako N, Aoki M.

Int J Hematol. 2018 Apr;107(4):460-467. doi: 10.1007/s12185-017-2390-2. Epub 2017 Dec 19.

PMID:
29260507
11.

[Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study].

Ando K, Chou T, Suzuki K, Shinagawa A, Uchida T, Taniwaki M, Hirata H, Ishizawa K, Matsue K, Okamoto S, Otsuka M, Matsumoto M, Iida S, Matsumura I, Ikeda T, Takezako N, Ogaki Y, Midorikawa S, Houck V, Ervin-Haynes A, Terui Y.

Rinsho Ketsueki. 2017;58(11):2219-2226. doi: 10.11406/rinketsu.58.2219. Japanese.

PMID:
29212972
12.

Surgical Apgar Score predicts 30-day morbidity in elderly patients who undergo non-laparoscopic gynecologic surgery: A retrospective analysis.

Kurata K, Chino Y, Shinagawa A, Kurokawa T, Yoshida Y.

Int J Surg. 2017 Dec;48:215-219. doi: 10.1016/j.ijsu.2017.11.002. Epub 2017 Nov 13.

13.

Pathological and gene expression analysis of a polygenic diabetes model, NONcNZO10/LtJ mice.

Hirata T, Yoshitomi T, Inoue M, Iigo Y, Matsumoto K, Kubota K, Shinagawa A.

Gene. 2017 Sep 20;629:52-58. doi: 10.1016/j.gene.2017.07.075. Epub 2017 Jul 29.

14.

Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine.

Kudo D, Shimizu M, Kuroda A, Suyama T, Shinagawa A, Ito S.

Rinsho Ketsueki. 2017;58(6):607-612. doi: 10.11406/rinketsu.58.607. Review. Japanese.

PMID:
28679990
15.

Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma.

Sakata-Yanagimoto M, Nakamoto-Matsubara R, Komori D, Nguyen TB, Hattori K, Nanmoku T, Kato T, Kurita N, Yokoyama Y, Obara N, Hasegawa Y, Shinagawa A, Chiba S.

Ann Hematol. 2017 Sep;96(9):1471-1475. doi: 10.1007/s00277-017-3038-2. Epub 2017 Jun 20.

PMID:
28634614
16.

18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma.

Yamamoto M, Tsujikawa T, Yamada S, Kurokawa T, Shinagawa A, Chino Y, Mori T, Kiyono Y, Okazawa H, Yoshida Y.

Oncotarget. 2017 Apr 4;8(14):22581-22589. doi: 10.18632/oncotarget.15127.

17.

Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102).

Ogiya D, Shibayama H, Nakatani E, Ando K, Suzuki K, Kuroda Y, Uchida T, Maruyama D, Matsumoto M, Matsue K, Iida S, Terui Y, Ri M, Chou T, Aotsuka N, Tabata S, Konishi J, Ohashi K, Shinagawa A, Sugiura I, Kuroda J, Miyamoto T, Ogura M, Tobinai K, Kanakura Y, Hotta T.

Rinsho Ketsueki. 2016;57(11):2311-2318. Japanese.

PMID:
27941278
18.

Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.

Kawamura K, Ikeda T, Hagiwara S, Mori T, Shinagawa A, Nishiwaki K, Ohashi K, Kubonishi S, Fukuda T, Ito T, Tomita N, Ichinohe T, Kato K, Morishima Y, Atsuta Y, Sunami K, Kanda Y.

Leuk Lymphoma. 2016 Sep;57(9):2077-83. doi: 10.3109/10428194.2016.1154958. Epub 2016 Mar 9.

PMID:
26961137
19.

Different Prognostic Implications of 18F-FDG PET Between Histological Subtypes in Patients With Cervical Cancer.

Rahman T, Tsujikawa T, Yamamoto M, Chino Y, Shinagawa A, Kurokawa T, Tsuchida T, Kimura H, Yoshida Y, Okazawa H.

Medicine (Baltimore). 2016 Mar;95(9):e3017. doi: 10.1097/MD.0000000000003017. Erratum in: Medicine (Baltimore). 2016 May 20;95(20):e0788.

20.

Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.

Suzuki K, Shinagawa A, Uchida T, Taniwaki M, Hirata H, Ishizawa K, Matsue K, Ogawa Y, Shimizu T, Otsuka M, Matsumoto M, Iida S, Terui Y, Matsumura I, Ikeda T, Takezako N, Ogaki Y, Midorikawa S, Houck V, Ervin-Haynes A, Chou T.

Cancer Sci. 2016 May;107(5):653-8. doi: 10.1111/cas.12916. Epub 2016 Mar 30.

21.

[A CASE OF GRANULOCYTIC SARCOMA IN THE BILATERAL URETER].

Miyagawa T, Tanaka K, Ikeda A, Komine M, Tsutsumi M, Shinagawa A.

Nihon Hinyokika Gakkai Zasshi. 2015 Jul;106(3):194-8. Japanese.

PMID:
26419078
22.

Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917.

Kubota K, Inaba S, Nakano R, Watanabe M, Sakurai H, Fukushima Y, Ichikawa K, Takahashi T, Izumi T, Shinagawa A.

Pharmacol Res Perspect. 2015 Jun;3(3):e00138. doi: 10.1002/prp2.138. Epub 2015 May 4.

23.

Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.

Cho Y, Hori M, Okoshi Y, Fujisawa F, Shinagawa A, Kudo D, Komeno T, Yoshida C, Katsura Y, Ota I, Shimizu S, Kamoshita M, Sasaki K, Tanaka K, Mukai HY, Kojima H.

Acta Haematol. 2015;134(1):25-31. doi: 10.1159/000369445. Epub 2015 Apr 3.

PMID:
25871926
24.

Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies.

Kamitsuji S, Matsuda T, Nishimura K, Endo S, Wada C, Watanabe K, Hasegawa K, Hishigaki H, Masuda M, Kuwahara Y, Tsuritani K, Sugiura K, Kubota T, Miyoshi S, Okada K, Nakazono K, Sugaya Y, Yang W, Sawamoto T, Uchida W, Shinagawa A, Fujiwara T, Yamada H, Suematsu K, Tsutsui N, Kamatani N, Liou SY; Japan PGx Data Science Consortium (JPDSC).

J Hum Genet. 2015 Jun;60(6):319-26. doi: 10.1038/jhg.2015.23. Epub 2015 Apr 9.

PMID:
25855068
25.

Bioactivation of loxoprofen to a pharmacologically active metabolite and its disposition kinetics in human skin.

Sawamura R, Sakurai H, Wada N, Nishiya Y, Honda T, Kazui M, Kurihara A, Shinagawa A, Izumi T.

Biopharm Drug Dispos. 2015 Sep;36(6):352-363. doi: 10.1002/bdd.1945. Epub 2015 Apr 21.

PMID:
25765700
26.

Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.

Inokuchi K, Kumagai T, Matsuki E, Ohashi K, Shinagawa A, Hatta Y, Takeuchi J, Yoshida C, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Okamoto S, Oba K, Sakamoto J, Sakamaki H.

J Clin Exp Hematop. 2014;54(3):197-204.

27.

Relation between outcomes and expression of estrogen receptor-α phosphorylated at Ser(167) in endometrioid endometrial cancer.

Kato E, Orisaka M, Kurokawa T, Chino Y, Fujita Y, Shinagawa A, Yoshida Y.

Cancer Sci. 2014 Oct;105(10):1307-12. doi: 10.1111/cas.12491. Epub 2014 Sep 26.

28.
29.

Ring-enhancement pattern on contrast-enhanced CT predicts adenosquamous carcinoma of the pancreas: a matched case-control study.

Imaoka H, Shimizu Y, Mizuno N, Hara K, Hijioka S, Tajika M, Tanaka T, Ishihara M, Ogura T, Obayashi T, Shinagawa A, Sakaguchi M, Yamaura H, Kato M, Niwa Y, Yamao K.

Pancreatology. 2014 May-Jun;14(3):221-6. doi: 10.1016/j.pan.2014.02.005. Epub 2014 Feb 25.

PMID:
24854619
30.

Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue.

Koyama K, Ogura Y, Nakai D, Watanabe M, Munemasa T, Oofune Y, Kubota K, Shinagawa A, Izumi T.

Drug Metab Dispos. 2014 Jun;42(6):1031-8. doi: 10.1124/dmd.114.057620. Epub 2014 Mar 28.

PMID:
24682756
31.

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.

Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, Kondo T, Motegi M, Kato Y, Mita M, Saito H, Yoshida C, Torimoto Y, Kimura T, Wano Y, Nomura J, Yamamoto S, Mayama K, Honma R, Sugawara T, Sato S, Shinagawa A, Abumiya M, Niioka T, Harigae H, Sawada K.

Biomark Res. 2014 Mar 20;2(1):6. doi: 10.1186/2050-7771-2-6.

32.

Can long-term follow-up strategies be determined using a nomogram-based prediction model of malignancy among intraductal papillary mucinous neoplasms of the pancreas?

Hijioka S, Shimizu Y, Mizuno N, Hara K, Imaoka H, Mekky MA, Bhatia V, Nagashio Y, Hasegawa T, Shinagawa A, Sekine M, Tajika M, Tanaka T, Ishihara M, Niwa Y, Yamao K.

Pancreas. 2014 Apr;43(3):367-72. doi: 10.1097/MPA.0000000000000033.

PMID:
24622065
33.

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.

Kumagai T, Matsuki E, Inokuchi K, Ohashi K, Shinagawa A, Takeuchi J, Yoshida C, Okamoto S, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Nishiwaki K, Oba K, Sakamoto J, Sakamaki H.

Int J Hematol. 2014 Jan;99(1):41-52. doi: 10.1007/s12185-013-1483-9. Epub 2013 Dec 3.

PMID:
24297450
34.

Bone healing of mandibular critical-size defects in spontaneously hypertensive rats.

Chin VK, Shinagawa A, Naclério-Homem Mda G.

Braz Oral Res. 2013 Sep-Oct;27(5):423-30. doi: 10.1590/S1806-83242013000500006.

35.

Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling.

Sakurai H, Kubota K, Inaba S, Takanaka K, Shinagawa A.

Mol Cell Proteomics. 2013 Aug;12(8):2313-23. doi: 10.1074/mcp.M112.023853. Epub 2013 May 14.

36.

Detection of ancestry informative HLA alleles confirms the admixed origins of Japanese population.

Nakaoka H, Mitsunaga S, Hosomichi K, Shyh-Yuh L, Sawamoto T, Fujiwara T, Tsutsui N, Suematsu K, Shinagawa A, Inoko H, Inoue I.

PLoS One. 2013;8(4):e60793. doi: 10.1371/journal.pone.0060793. Epub 2013 Apr 5.

37.

Prospective clinical study of endoscopic ultrasound-guided choledochoduodenostomy with direct metallic stent placement using a forward-viewing echoendoscope.

Hara K, Yamao K, Hijioka S, Mizuno N, Imaoka H, Tajika M, Kondo S, Tanaka T, Haba S, Takeshi O, Nagashio Y, Obayashi T, Shinagawa A, Bhatia V, Shimizu Y, Goto H, Niwa Y.

Endoscopy. 2013;45(5):392-6. doi: 10.1055/s-0032-1326076. Epub 2013 Jan 21.

PMID:
23338620
38.

[Epidemiological study of A (H1N1) pdm09 in Iki Island, Nagasaki].

Eda K, Otaguro S, Matsushima T, Shinagawa A, Ikematsu H, Kashiwagi S.

Kansenshogaku Zasshi. 2012 May;86(3):274-81. Japanese.

PMID:
22746049
39.

Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.

Endo S, Fukahori A, Tokuhiro S, Shinagawa A, Walker J, Yoshihara K, Ishizuka H, Ieiri I, Sugiyama Y.

J Hum Genet. 2012 Aug;57(8):531-44. doi: 10.1038/jhg.2012.63. Epub 2012 Jun 14.

PMID:
22695893
40.

[Clinicopathological features of 8 patients with metastatic gastric tumors].

Akabane A, Tajika M, Kondo S, Tanaka T, Mizuno N, Hara K, Hijioka S, Imaoka H, Saeki A, Ogura T, Haba S, Nagashio Y, Hasegawa T, Oobayashi T, Shinagawa A, Yamao K, Yatabe Y, Niwa Y.

Nihon Shokakibyo Gakkai Zasshi. 2012 Apr;109(4):585-92. Japanese.

PMID:
22481259
41.

[Reported use of thalidomide in multiple myeloma: presentation of problems in the Thaled® outpatient department].

Aimono Y, Sato W, Otani E, Isa S, Sawahata T, Onozaki M, Saito Y, Ebata S, Aoyama Y, Hakozaki M, Suzuki M, Kudo D, Monma Y, Chikatsu N, Shinagawa A.

Gan To Kagaku Ryoho. 2011 Dec;38(13):2579-84. Japanese.

PMID:
22189222
42.

Evaluation of hepatic glutathione transferase Mu 1 and Theta 1 activities in humans and mice using genotype information.

Arakawa S, Fujimoto K, Kato A, Endo S, Fukahori A, Shinagawa A, Fischer T, Mueller J, Takasaki W.

Drug Metab Dispos. 2012 Mar;40(3):497-503. doi: 10.1124/dmd.111.042911. Epub 2011 Dec 14.

PMID:
22170331
43.

The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells.

Shinagawa A, Yoshida Y, Kurokawa T, Horiuchi Y, Tsuyoshi H, Orisaka M, Sawamura Y, Kleinman HK, Kotsuji F.

Int J Oncol. 2011 Dec;39(6):1359-64. doi: 10.3892/ijo.2011.1134. Epub 2011 Jul 20.

PMID:
21935568
44.

Catastrophic progression of preterm delivery caused by 2009 H1N1 influenza infection.

Nishijima K, Kurokawa T, Shinagawa A, Uchinami I, Tsuyoshi H, Kotsuji F.

J Emerg Nurs. 2011 Sep;37(5):435-6. doi: 10.1016/j.jen.2011.06.018. Review. No abstract available.

PMID:
21889650
45.

Transient elevation of international normalized ratio during cisplatin-based chemotherapy in patients who are taking warfarin.

Yano R, Kurokawa T, Tsuyoshi H, Shinagawa A, Sawamura Y, Matsunaga A, Nakamura T, Yoshida Y, Yoneda M, Kotsuji F, Masada M.

Ann Pharmacother. 2011 Oct;45(10):e55. doi: 10.1345/aph.1Q290. Epub 2011 Aug 31.

PMID:
21881031
46.

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia.

Yoshida C, Komeno T, Hori M, Kimura T, Fujii M, Okoshi Y, Suzukawa K, Chiba S, Hasegawa Y, Mukai HY, Ito T, Shimizu S, Kamoshita M, Kudo D, Shinagawa A, Chikatsu N, Monma Y, Watanabe N, Kojima H.

Int J Hematol. 2011 May;93(5):618-623. doi: 10.1007/s12185-011-0838-3. Epub 2011 Apr 22.

PMID:
21523339
47.

Assessment of preclinical learning on oral surgery using three instructional strategies.

Dantas AK, Shinagawa A, Deboni MC.

J Dent Educ. 2010 Nov;74(11):1230-6.

48.

POSH promotes cell survival in Drosophila and in human RASF cells.

Tsuda M, Kawaida R, Kobayashi K, Shinagawa A, Sawada T, Yamada R, Yamamoto K, Aigaki T.

FEBS Lett. 2010 Nov 19;584(22):4689-94. doi: 10.1016/j.febslet.2010.10.048. Epub 2010 Oct 26.

49.

Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer.

Yoshida Y, Kurokawa T, Horiuchi Y, Sawamura Y, Shinagawa A, Kotsuji F.

Eur J Cancer. 2010 Dec;46(18):3445-52. doi: 10.1016/j.ejca.2010.09.004.

PMID:
20926288
50.

Raldh3 expression in diabetic islets reciprocally regulates secretion of insulin and glucagon from pancreatic islets.

Shimamura M, Karasawa H, Sakakibara S, Shinagawa A.

Biochem Biophys Res Commun. 2010 Oct 8;401(1):79-84. doi: 10.1016/j.bbrc.2010.09.013. Epub 2010 Sep 15.

PMID:
20833146

Supplemental Content

Loading ...
Support Center